Skip to main content
. 2017 Jan 5;17:10. doi: 10.1186/s12872-016-0450-9

Table 2.

Baseline characteristics of patients among different mean non-HDL-C groups

Parameter Non-HDL-C <100 mg/dl (N = 299, 34%) Non-HDL-C 100–130 mg/dl (N = 333, 38%) Non-HDL-C >130 mg/dl (N = 236, 27%) P-value
Age (years) 65.9 ± 11.0 62.5 ± 11.1 60.6 ± 11.0 <0.001
Male 66.2% 60.1% 59.3% 0.173
Body mass index (kg/m2) 22.5 ± 4.5 23.0 ± 5.5 23.4 ± 3.9 0.252
LVEF (%) 49.9 ± 14.4 50.8 ± 13.0 50.0 ± 14.2 0.715
Creatinine (mg/dl) 2.1 ± 8.7 1.7 ± 6.8 1.4 ± 2.2 0.528
Hemoglobin (g/dl) 12.5 ± 2.5 12.5 ± 2.1 12.6 ± 2.0 0.681
Baseline LDL-C (mg/dl) 101.1 ± 38.5 116.1 ± 39.6 131.7 ± 46.1 <0.001
Baseline non-HDL-C (mg/dl) 122.1 ± 38.7 142.1 ± 42.5 164.3 ± 51.4 <0.001
Baseline HDL-C (mg/dl) 39.7 ± 11.3 40.2 ± 11.0 39.8 ± 10.5 0.822
Smoking 37.8% 35.0% 38.6% 0.850
Hypertension 57.9% 59.2% 53.8% 0.477
Dyslipidemia 25.8% 34.2% 38.6% 0.0.05
Diabetes mellitus 27.1% 26.4% 28.0% 0.920
Chronic kidney disease 9.0% 5.4% 7.2% 0.210
History of CAD 8.4% 9.0% 14.0% 0.07
History of stroke 5.0% 3.9% 4.7% 0.788
STEMI 79.3% 79.9% 72.5% 0.181
Statin 93.0% 92.8% 93.2% 0.981
Ezetimibe 3.3% 2.4% 6.8% 0.024

CAD coronary artery disease, LVEF left ventricular ejection fraction, STEMI ST elevation myocardial infarction